JSE Sens

Closing date of IPO - Friday, 4 November

2022/11/02 09:00:00

Download PDF Stock report

                    Closing date of IPO - Friday, 4 November

 (Incorporated in South Africa)
 (Registration number 2022/320351/06)
 Ordinary Shares Share code: CCC
 ISIN: ZAE000310397
 (“the Company”)


Further to the Exchange News Service of the JSE Limited announcement on 12 September where Cilo Cybin
Holdings Limited informed the market of its intention to raise a Minimum Amount of R500 million by means of an
IPO and list on the JSE main board, the Company would like to remind interested investors of the dates as set out
in the Prospectus.

Cilo Cybin Holdings Limited was incorporated by the Founder, Gabriel Theron, for the purposes of being listed on
the Main Board of the JSE with effect from the commencement of trade on Monday, 14 November 2022, as a special
purpose acquisition company to pursue acquisitions of, and investments in, commercial enterprises operating in
the Biotech, Biohacking or Pharmaceutical sector that will enable it to develop and expand methodologies by utilising
Artificial Intelligence (AI) and expertise of medical specialists to deliver holistic and individualised solutions to
customers to better their health, performance and increase their longevity. The Prospectus and other supporting
documentation are available on the website.

The industries Cilo Cybin envisions to participate in include Biotech, Cannabis, Psychedelics, wearable devices and
custom nutrition. The Company has identified potential opportunities to acquire several assets located in South
Africa and United States of America (which are still subject to shareholder approval). One of these assets are Cilo
Cybin Pharmaceutical Proprietary Limited (“CCP”). Gabriel Theron is also the founder and main shareholder in CCP.
CCP has a state-of-the-art cultivation, manufacturing and packaging facility in Midrand. The vision of the Company,
from the outset, was not to sell cannabis flower, as a final product but rather processed pharmaceutical grade
products. CCP holds a GACP license from the regulator in South Africa, SAHPRA to cultivate cannabis and a second
license for the manufacturing of an Active Pharmaceutical Ingredient (API) oil and to manufacture final labelled
pharmaceutical grade product, making CCP the first Company in South Africa to have both GACP and GMP
cannabis licenses in one Company. CCP not only develops, manufactures and distributes its own branded products
but also manufactures pharmaceutical grade products for local and international third parties on a tolling basis.

Globally cannabis, psychedelics and overall physical and mental health have become high growth, high margin,
attractive businesses to invest in. CCP has been operating in this sector since 2018 (for 4 years) formulating and
producing its own branded product and are leaders in this market segment.


 Opening date of the IPO (09h00)                                                 Monday, 12 September
 Closing date of the IPO (12h00)                                                   Friday, 4 November
 Finalisation Results of the IPO released on SENS                                 Tuesday, 8 November
 Notification of allotments to successful investors by                            Tuesday, 8 November
 Finalisation Results of the IPO published in the press on                      Wednesday, 9 November
 Proposed date of Listing (09h00)                                                 Monday, 14 November

To register an interest in the IPO and to receive IPO related documentation send an email to ipo@cilocybin.com or
visit www.cilocybin.com

2 November 2022

DEA-RU Proprietary Limited

Date: 02-11-2022 09:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.